Helix is a biopharmaceutical company specializing in the field of cancer treatment. The Company’s headquarters is located in Toronto, Canada, while its Polish branch in the form of the subsidiary Helix Polska is located in Warsaw. The company is actively developing innovative products used in the prevention and treatment of cancer based on its own proprietary technologies. Corporate initiatives in the development of drugs are based on two innovative technology platforms: DOS47, that is innovation in the treatment of malignant solid tumors and BIPHASIX used in the treatment of precancerous cervical lesions.
Helix BioPharma Corporation is currently listed on the Toronto and Frankfurt Stock Exchange. Business strategy involves maximizing its value through the development of L-DOS47 and other drugs based on DOS47 technology platform by giving them the status of the product of Phase II of clinical trials.